ERBB2 and breast cancer: A total of 132 patients with HER2-positive breast cancer were analyzed, and the results showed that the HER2-I655V genotype was significantly associated with cardiotoxicity, whereas the FCGR2A-131 H/H genotype was markedly associated with shorter event-free survival (EFS).